AAT-AD/PD 2018 - Press Release

Press Release

Download the press release in PDF here

Focusing on treatment of Alzheimer’s disease and Parkinson’s disease

AD/PDTM Announces a Joint Focus Meeting in 2018 with the International Geneva/ Springfield Symposium on Advances in Alzheimer Therapy (AAT)

A new joint meeting called Advances in Alzheimer’s and Parkinson’s Therapies, An AAT-AD/PDTM Focus Meeting was announced as the world’s neurodegenerative disease specialists gathered March 29 – April 2, 2017 in Vienna, Austria at the premier biennial showcase for the latest research and scientific discoveries in neurodegenerative diseases: AD/PDTM 2017, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders.

The AAT-AD/PDTM Focus Meeting 2018 will take place in Torino, Italy, 15-18 March 2018. The Conference will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer's, Parkinson's and other related neurological disorders. A central theme will be to advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers. This Conference will focus on driving successful collaborations among academia and industry, leading to the development of innovative drugs and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.

The AAT-AD/PDTM Focus Meeting 2018 will be co-organized by both conferences’ executives: Abraham Fisher, Ezio Giacobini, Gabriel Gold, Roger Nitsch and Manfred Windisch.

The Conference, being in Torino, is dedicated to the Nobel Laureate, Rita Levi-Montalcini, who was born and worked in Torino.

“We, the organizing committee, see this as a great opportunity to create continuity in the field from year to year with a strong emphasis on therapy on alternate years. We hope to harness the strengths of both conferences and offer a platform to highlight the hottest and most relevant topics, both in Alzheimer’s and Parkinson’s therapies as well as related neurological diseases.”

The organizing committee strongly believes that the joining of these two well established and high quality meetings will provide one of the best platforms in the field for industry, scientists and clinicians with the ultimate goal of benefiting all patients suffering from Alzheimer’s, Parkinson’s and neurodegenerative diseases. “This Conference provides a vital opportunity for the international community to come together and strive for better advancements in the year leading up to AD/PDTM 2019 in Lisbon, Portugal.”

This year in Vienna, AD/PDTM 2017 saw continual conference-on-conference growth with over 3200 participants, 1645 accepted posters and over 640 session presenters.



About the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM):

Founded in 1985, AD/PDTM is a landmark event bringing together neuroscientists, pharmacologists and clinicians to study the hot topics and scientific breakthroughs associated with Alzheimer’s Disease, Parkinson’s Disease and related neurological disorders, and to evaluate advances that might ameliorate many of these diseases. AD/PDTM combines all the neurodegenerative diseases under one roof to uniquely look at their similarities on the one hand and their differences on the other. It is the main platform for the world’s experts to present their latest findings and research in diagnosis, prevention and discovery of new treatment targets for these debilitating disorders.

About the International Geneva/ Springfield Symposium: Advances in Alzheimer Therapy (AAT):

For over a quarter century of excellence AAT has brought together science and clinical knowledge. Since 1988, leading clinicians and scientists have met every 2 years to discuss new targets and drugs for Alzheimer’s disease and novel approaches to current therapy. Important topics have included drug discovery and treatment development, new preclinical models, clinical trials, early diagnosis, advances in brain imaging and biomarkers.

Contact Information:
For more information, contact:
AAT-AD/PDTM 2018 Secretariat
Kenes Group                                                                                       
Tel. + +41 22 9080488

Keep Me Updated